title: Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
abstract: BACKGROUND
  This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.
  
  
  METHODS
  Patients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received docetaxel and a fluoropyrimidine with or without panitumumab for 8 cycles or until progression. The primary end point was response rate (RECIST1.1). We planned to enrol 100 patients, with 50% expected response rate for combination therapy.
  
  
  RESULTS
  A total of 77 patients were enrolled. A safety alert from the REAL3 trial prompted a review of data that found no evidence of adverse outcomes associated with panitumumab but questionable efficacy, and new enrolment was ceased. Enrolled patients were treated according to protocol. Response rates were 49% (95% CI 34-64%) in the chemotherapy arm and 58% (95% CI 42-72%) in the combination arm. Common grade 3 and 4 toxicities included infection, anorexia, vomiting, diarrhoea and fatigue. At 23.7 months of median follow-up, median progression-free survival was 6.9 months vs 6.0 months and median overall survival was 11.7 months vs 10.0 months in the chemotherapy arm and the combination arm, respectively.
  
  
  CONCLUSIONS
  Adding panitumumab to docetaxel-based chemotherapy for advanced oesophagogastric cancer did not improve efficacy and increased toxicities.
authors: Austin Health, PO Box 5555, Heidelberg, VIC 3084, Australia.
authors: Niall C
authors: NC
authors: Tebbutt
authors: The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, SA 5011, Australia.
authors: Timothy J
authors: TJ
authors: Price
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Danielle A
authors: DA
authors: Ferraro
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Nicole
authors: N
authors: Wong
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Anne-Sophie
authors: AS
authors: Veillard
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Merryn
authors: M
authors: Hall
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Katrin M
authors: KM
authors: Sjoquist
authors: Royal North Shore Hospital, Pacific Highway, St Leonards, Sydney, NSW 2064, Australia.
authors: Nick
authors: N
authors: Pavlakis
authors: Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia.
authors: Andrew
authors: A
authors: Strickland
authors: Townsville Hospital, 100 Angus Smith Drive, Douglas, Townsville, QLD 4814, Australia.
authors: Suresh C
authors: SC
authors: Varma
authors: Box Hill Hospital, Nelson Road, Box Hill, VIC 3128, Australia.
authors: Prasad
authors: P
authors: Cooray
authors: Royal Hobart Hospital, 48 Liverpool Street, Hobart, TAS 7000, Australia.
authors: Rosemary
authors: R
authors: Young
authors: Border Medical Oncology, 63-69 Nordsvan Drive, Albury, Wodonga, NSW 3690, Australia.
authors: Craig
authors: C
authors: Underhill
authors: Nepean Cancer Care Centre, Derby Street, Kingswood, Penrith, NSW 2747, Australia.
authors: Jennifer A
authors: JA
authors: Shannon
authors: Frankston Hospital, PO Box 52, Frankston, Melbourne, VIC 3199, Australia.
authors: Vinod
authors: V
authors: Ganju
authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
authors: Val
authors: V
authors: Gebski
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003967:Diarrhea / Q000139:chemically induced; D018572:Disease-Free Survival; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004943:Esophagogastric Junction / Q000473:pathology*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007239:Infections / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D000077544:Panitumumab; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D043823:Taxoids; D000077143:Docetaxel; D000069287:Capecitabine; D000077544:Panitumumab; D002945:Cisplatin; D005472:Fluorouracil